← Leaderboards
Joseph R Pisegna
University Of California Los Angeles
$1,249,305
Attributed
$1,249,305
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $0 · FY2012–22$1$1$1$0$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,249,305 · 3
VA$0 · 3
By mechanism
M01$1,249,305 · 3
I01$0 · 2
IS1$0 · 1
Top collaborators
- Yvette France Tache5 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Helen E Raybould$11,094,173
- Sherin U. Devaskar$31,339,941
- Juan Enrique Rozengurt$20,476,723
- Yvette France Tache$17,660,715
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsVeteransResourcesBaseHealthcareRegulationHuman SubjectSecretionIncidenceHuman Therapy EvaluationGastric AcidPreventionClinical ResearchSignal TransductionDiabetes MellitusDrug Screening /EvaluationZollinger Ellison SyndromeObesityIntravenous AdministrationPathway InteractionsHealthcare SystemsGastrointestinal AgentsGastrointestinal Disorder ChemotherapyDiet
Grant awards (19)
CMA: Cancer Stem Cells in the Pathogenesis and Treatment of Colorectal Cancer$0
I01 · FY2022 · VA · contact PI
CMA: Cancer Stem Cells in the Pathogenesis and Treatment of Colorectal Cancer$0
I01 · FY2021 · VA · contact PI
CMA: Cancer Stem Cells in the Pathogenesis and Treatment of Colorectal Cancer$0
I01 · FY2020 · VA · contact PI
ShEEP Request for Acquisition a 10x Genomics Single Cell RNA Sequencer$0
IS1 · FY2019 · VA · contact PI
CMA: Cancer Stem Cells in the Pathogenesis and Treatment of Colorectal Cancer$0
I01 · FY2019 · VA · contact PI
Gastrointestinal Hormonal Regulation of Obesity$0
I01 · FY2015 · VA · contact PI
Gastrointestinal Hormonal Regulation of Obesity$0
I01 · FY2014 · VA · contact PI
Gastrointestinal Hormonal Regulation of Obesity$0
I01 · FY2014 · VA · contact PI
Gastrointestinal Hormonal Regulation of Obesity$0
I01 · FY2014 · VA · contact PI
Gastrointestinal Hormonal Regulation of Obesity$0
I01 · FY2012 · VA · contact PI
GASTRIC ACID SECRETION RESPONSE IN PATIENTS W/ GASTROESOPHAGEAL REFLUX DISEASE$207,266
M01 · FY2001 · RR
PIVOTAL EFFICACY STUDY OF INHIBITION OF GASTRIC ACID SECRETION BY PANTOPRAZOLE$207,266
M01 · FY2001 · RR
INHIBITION OF GASTRIC ACID SECRETION BY INTRAVENOUS PANTOPRAZOLE IN ZES PATIENTS$207,266
M01 · FY2001 · RR
GASTRIC ACID SECRETION RESPONSE IN PATIENTS W/ GASTROESOPHAGEAL REFLUX DISEASE$207,266
M01 · FY2000 · RR
PIVOTAL EFFICACY STUDY OF INHIBITION OF GASTRIC ACID SECRETION BY PANTOPRAZOLE$207,266
M01 · FY2000 · RR
INHIBITION OF GASTRIC ACID SECRETION BY INTRAVENOUS PANTOPRAZOLE IN ZES PATIENTS$207,266
M01 · FY2000 · RR
INHIBITION OF GASTRIC ACID SECRETION BY INTRAVENOUS PANTOPRAZOLE IN ZES PATIENTS$1,903
M01 · FY2000 · RR
PIVOTAL EFFICACY STUDY OF INHIBITION OF GASTRIC ACID SECRETION BY PANTOPRAZOLE$1,903
M01 · FY2000 · RR
GASTRIC ACID SECRETION RESPONSE IN PATIENTS W/ GASTROESOPHAGEAL REFLUX DISEASE$1,903
M01 · FY2000 · RR